Clinical trial · Interventional
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): target number of subject not reached
Summary
Brief summary (as posted)
Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization. Development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors. Angiomyolipomas have been shown to regress after prolonged treatment with mTOR inhibitors (Sirolimus), but with a large proportion of secondary effects. We showed recently that beta-blockers were able to induce regression of infantile hemagiomas. Consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the presence of beta2 receptors. The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Angiomyolipomas | — | UNRESOLVED | — |
| Tuberous Sclerosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propranolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patient
- interventionNames
- Drug: Propranolol
Primary outcomes (1)
- measure
- Evolution of angiomyolipomas volume
- timeFrame
- 6 months and 1 year after inclusion
- description
- Stabilization or even regression of angiomyolipomas volume after 6 months and 1 year of treatment with a quantification of the vascular component.
Secondary outcomes (4)
- measure
- Renal function evolution
- timeFrame
- 6 months and 1 year after inclusion
- description
- Improvement of renal function after 6 months and 1 year of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Tuberous sclerosis patients with one or several angiomyolipomas of a size of at least 4 cms. Exclusion Criteria: * Patients whom CT or MR scan shows one or several intra-lesional aneurisms requiring a preventive embolization. * Patients with a retroperitoneal hemorragic complication requiring a preventive embolization. * Patients whom biopsy will show an adenocarcinoma, hypertension non controlled, renal failure and severe liver. * Diabetic subjects insufficiently controlled. * Beta-blockers contra-indication. * Psychosis, severe mental disorder. * Patient already treated with beta-blockers or mTOR inhibitors. * Pregnant or nursing women.
References
Publications (0)
Data not yet available